ONCOSTATIN M-SPECIFIC RECEPTOR EXPRESSION AND FUNCTION IN REGULATING CELL PROLIFERATION OF NORMAL AND MALIGNANT MAMMARY EPITHELIAL CELLS

• Published in: Cytokine (Philadelphia, Pa.) Vol. 10; no. 4; pp. 295 - 302
• Main Authors: Liu, Jingwen, Hadjokas, Nicholas, Mosley, Bruce, Estrov, Zeev, Spence, Michael J., Vestal, Robert E.
• Format: Journal Article
• Language: English
• Published: England Elsevier Ltd 01.04.1998
• Subjects: Binding Sites; Breast - cytology; Cell Division - drug effects; Cells, Cultured; Epithelial Cells - cytology; Epithelial Cells - drug effects; Epithelial Cells - metabolism; Female; Gene Expression; Growth Inhibitors - pharmacology; Growth Inhibitors - physiology; Humans; Interleukin-6; Leukemia Inhibitory Factor; Lymphokines - pharmacology; Lymphokines - physiology; Oncostatin M; oncostatin M/leukaemia inhibitor factor/gp130/cytokine receptors/cell proliferation; Peptides - metabolism; Peptides - pharmacology; Polymerase Chain Reaction; Receptors, Cytokine - genetics; Receptors, Cytokine - metabolism; Receptors, Cytokine - physiology; Receptors, Oncostatin M; RNA, Messenger; Tumor Cells, Cultured; oncostatin M/leukaemia inhibitor factor/gp130/cytokine receptors/cell proliferation
• ISSN: 1043-4666; 1096-0023
• DOI: 10.1006/cyto.1997.0283

Oncostatin M (OSM) is a cytokine produced by activated T lymphocytes and macrophages. OSM is structurally and functionally related to leukaemia inhibitory factor (LIF), another cytokine in the interleukin 6 (IL-6) family. The biological activities of OSM are mediated through two types of receptor complexes, the LIF/OSM shared receptor (type I) and OSM-specific receptor (OSM-R type II), which is composed of gp130 as a binding subunit and a newly identified affinity conversion subunit, OSM-Rβ. Previous research conducted in the authors' laboratory has shown that OSM inhibits the growth of several breast cancer cell lines. To investigate whether OSM has a similar effect in primary normal human mammary epithelial (HME) cells, the activity of OSM in HME cells derived from four donors was examined. OSM produced a dose-dependent inhibition of DNA synthesis in these cells. In order to determine the receptor subtypes mediating OSM activity in HME and breast cancer cells, flow cytometry analysis using anti-gp130mAb and anti-OSM-RβmAb was performed. In these studies, the authors were able to examine expression of gp130 and OSM-Rβ. In addition, quantitative RT-PCR assays were conducted to measure expressions of the mRNAs of the subunits for type I and II OSM receptor. The results show that HME cells and most breast cancer cell lines express both the type I and the type II OSM receptors. However, type II, OSM-specific receptors are expressed at a higher level than type I, OSM/LIF shared receptors. Accordingly, we compared the growth regulatory activities of OSM with LIF in HME cells and in breast cancer cells. In contrast to the inhibitory activity of OSM, LIF stimulated the growth of breast cancer cells, whereas it had no effect on normal mammary epithelial cell growth. Together, these data suggest that OSM plays an inhibitory role in normal and malignant mammary epithelial cell growth in vitro. OSM activity is mediated by the OSM-specific receptor (type II), not by the OSM/LIF shared receptor.